Skip to content

Pieris Pharma started at buy by Rodman & Renshaw

May 30, 2017

Rodman & Renshaw initiates coverage on Pieris Pharmaceuticals (NASDAQ: PIRS) with a Buy rating and a price target of $9.00.

Analyst Dr. Joe Pantginis comments “Pieris has signed a broad set of collaborations for early stage anticalin research and development. We believe a sea change has been seen in 2017 with regard to the scope and breadth of Pieris’ business development activities. Two major partnerships have been signed with Servier and AstraZeneca. In total, all of Pieris’ current partnerships have the potential for >$4.5 billion in milestone payments plus royalties.”


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: